Cytokine release syndrome (CRS) following treatment with tebentafusp, a novel bispecific TCR-anti-CD3 directed against gp100, in patients with advanced melanoma
Shoushtari, A Middleton, M Stevens, N Evans, T Infante, J Sznol, M Anthoney, A Gupta, Avinash Woodcock, V Wiseman, T
Shoushtari, A
Middleton, M
Stevens, N
Evans, T
Infante, J
Sznol, M
Anthoney, A
Gupta, Avinash
Woodcock, V
Wiseman, T
Citations
Altmetric:
Abstract
Description
Date
2019
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Shoushtari A, Middleton M, Stevens N, Evans T, Infante J, Sznol M, et al. Cytokine release syndrome (CRS) following treatment with tebentafusp, a novel bispecific TCR-anti-CD3 directed against gp100, in patients with advanced melanoma. Journal for Immunotherapy of Cancer. 2019;7